Paris, France, February 14, 2006 Sanofi-aventis announced that the results of the RIO North America trial were published today in The Journal of the American Medical Association (JAMA). The trial evaluated two-year treatment with rimonabant in overweight or obese patients, many of whom were at increased risk for diabetes and heart disease through the presence of additional risk factors.
Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.
Svenska Cardiologföreningen och sanofi-aventis utlyser ett stipendium om 150 000 kronor inom området kardiometabol risk.
The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
Excellent performance from vaccines: up 26.9% on a comparable basis1 2005 adjusted earnings1 guidance raised Approval of Plavix® in Japan
Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients with acute STsegment elevation myocardial infarction (STEMI).
Sanofi-aventis announced today the signature of an agreement to transfer its rights to Exuberaâ, an inhaled human insulin, to Pfizer.
Lyon, France 21 December 2005 Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteurs human vaccine products. Läs resterande pressmeddelande i
Vice President Communications sanofi pasteur: Alain BERNAL U. S. Media Relations: Len LAVENDA Tel.: +1 570 839 7187 - Fax: +1 570 839 0955 - Sanofi Pasteur Inc. - Discovery Drive - Swiftwater, PA 18370-0187 - USA - www.sanofipasteur.com ~ Data Show that the Vaccine Is Safe, Demonstrates Immunogenicity and Provides Future Direction For Development ~ Lyon, France December 15, 2005 Sano
Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (TCH) with TAXOTERE® (docetaxel), the platinum salt carboplatin and HERCEPTIN® (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer Paris and San Antonio December 8th, 2005 The Breast Cancer International Research Group
Paris December 2, 2005 Sanofi-aventis announced today that the U.S Food and Drug Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere (docetaxel) Injection Concentrate, in combination with a current standard treatment (cisplatin and 5-fluorouracil) for advanced gastric cancer. The supplemental application is based on d
